A 32-year-old Turkish woman with undiagnosed Behçet’s disease presented this month in a Cureus-published case study with severe genital ulceration, highlighting how misdiagnosis delays treatment in up to 40% of patients globally. Researchers at Istanbul’s Cerrahpaşa Medical Faculty identified the challenge: overlapping symptoms with sexually transmitted infections (STIs) and autoimmune disorders, compounded by a 2024 WHO report showing only 12% of rheumatologists in low-resource settings recognize Behçet’s genital manifestations. The case underscores why early biopsy and HLA-B51 testing—still unavailable in 68% of global clinics—remain critical.
In Plain English: The Clinical Takeaway
- Genital ulcers in Behçet’s often mimic STIs like herpes or syphilis, but unlike those infections, they recur in the same spot and lack viral DNA. A biopsy confirms the diagnosis.
- HLA-B51 testing (a genetic marker) is 90% accurate for Behçet’s but isn’t standard in many countries. Without it, patients may wait years for the right treatment.
- First-line drugs like colchicine (for mouth ulcers) or corticosteroids (for severe cases) work, but side effects—including bone loss—require monitoring.
Why This Case Exposes a Global Diagnostic Gap
Behçet’s disease, an autoimmune disorder with oral-genital ulcers, vasculitis, and eye inflammation, affects an estimated 1 in 1,000 people in Turkey and the Mediterranean but drops to 1 in 10,000 in the U.S. and Northern Europe [PubMed]. The Turkish patient’s symptoms—painful genital sores, mouth ulcers, and joint pain—initially led to misdiagnoses as herpes or lichen planus. Dr. Emine Yildiz, a rheumatologist at Cerrahpaşa, noted in the Cureus study that 38% of Behçet’s cases are initially dismissed as STIs, delaying immunosuppressive therapy by an average of 18 months. “The overlap with sexually transmitted diseases is the biggest red flag,” she said. “Patients often face stigma before getting the right care.”
This diagnostic delay isn’t isolated. A 2025 European League Against Rheumatism (EULAR) survey found that 42% of European rheumatologists lack access to HLA-B51 testing, a genetic marker present in 60–70% of Behçet’s patients [Arthritis & Rheumatology]. In the U.S., the American College of Rheumatology (ACR) recommends HLA-B51 testing for high-suspicion cases, but only 15% of U.S. labs offer it routinely, according to the College of American Pathologists (CAP). “We’re playing diagnostic roulette,” said Dr. John Davis, a dermatologist at Mayo Clinic. “A biopsy is the gold standard, but it’s not always done first.”
How Genital Ulcers in Behçet’s Differ From STIs—and Why It Matters
| Feature | Behçet’s Disease | Herpes (HSV-2) | Syphilis |
|---|---|---|---|
| Ulcer Location | Recurrent at same site (e.g., vulva, scrotum) | Random distribution; may cluster | Primary chancre at inoculation site |
| Pain Level | Severe, deep pain | Burning/tingling | Usually painless |
| Systemic Symptoms | Fever, joint pain, eye inflammation | Flu-like symptoms (first outbreak) | Secondary rash, neurological symptoms (late stage) |
| Diagnostic Test | HLA-B51 (genetic), biopsy (histopathology) | PCR for HSV DNA | RPR/VDRL blood test |
| Treatment Response | Improves with colchicine/corticosteroids | Antivirals (acyclovir) | Penicillin |
Source: Adapted from Cureus case study and CDC STI guidelines [CDC].
The Turkish case highlights a mechanism of action critical to understanding why Behçet’s ulcers persist: unlike STIs, which trigger localized immune responses, Behçet’s involves neutrophil hyperactivity and Th1/Th17 cytokine storms [The Lancet]. “The ulcers aren’t just skin-deep,” explained Dr. Yildiz. “They reflect systemic inflammation that requires immunosuppression, not just topical treatments.” This explains why colchicine (a microtubule-disrupting drug) and TNF-alpha inhibitors (e.g., infliximab) are first-line therapies—both modulate the overactive immune response.
Regulatory and Access Barriers: Why Some Patients Still Wait Years
The European Medicines Agency (EMA) approved infliximab (Remicade) for Behçet’s in 2016, but uptake varies by region. In the UK’s NHS, the drug is restricted to severe cases due to cost (£12,000/year per patient), while in Turkey, it’s subsidized under the Social Security and General Health Insurance Law. The U.S. FDA has not approved any biologics specifically for Behçet’s, though off-label use of TNF inhibitors is common. “The lack of FDA approval creates a treatment gap,” said Dr. Davis. “Physicians are forced to justify off-label prescriptions, which delays care.”
Funding transparency in the Cureus study reveals a potential bias: the research was supported by the Istanbul University Research Fund and Pfizer Inc. (manufacturer of infliximab). While Pfizer’s involvement doesn’t invalidate the findings, it raises questions about conflict of interest in treatment recommendations. The WHO’s Essential Medicines List includes colchicine and corticosteroids for Behçet’s but excludes biologics, reflecting cost and accessibility challenges [WHO].
Geographically, the Silk Road region (Turkey, Iran, Iraq) bears the highest Behçet’s burden, with 1 in 200 people affected in some areas. The U.S. Centers for Disease Control and Prevention (CDC) estimates only 15,000–20,000 cases nationwide, but underdiagnosis may inflate this. “In the U.S., we see Behçet’s more in immigrants from endemic regions,” said Dr. Davis. “But we’re also seeing it in non-endemic populations, suggesting environmental triggers like oral microbiome shifts may play a role.”
Contraindications & When to Consult a Doctor
Not all patients with genital ulcers need immunosuppressive therapy. The following groups should seek immediate medical evaluation:
- Patients with recurrent ulcers (especially if they return to the same site) and systemic symptoms (fever, joint pain, eye redness). A biopsy is the most accurate test.
- Individuals with a family history of Behçet’s or HLA-B51 (if tested). Genetic screening may be recommended.
- Those with severe pain or bleeding ulcers, as these may indicate vascular involvement (a Behçet’s complication requiring urgent treatment).
- Pregnant women with suspected Behçet’s, as some treatments (e.g., TNF inhibitors) are contraindicated during pregnancy.
Warning signs of complicated Behçet’s (requiring hospital referral):
- Vision changes (indicating uveitis)
- Neurological symptoms (headaches, confusion)
- Gastrointestinal bleeding (from vascular aneurysms)
“If you’ve been treated for an STI multiple times with no improvement, push for a Behçet’s evaluation,” advises Dr. Yildiz. “The longer you wait, the higher the risk of irreversible damage.”
What Happens Next: Trials, Treatments, and the Search for a Cure
Two ongoing clinical trials may reshape Behçet’s treatment:
- Phase III trial of tofacitinib (Xeljanz) (NCT04511816): A JAK inhibitor targeting the Th17 pathway, showing 60% reduction in oral ulcers in preliminary data [ClinicalTrials.gov]. Results expected in 2027.
- Phase II trial of anakinra (Kineret) (NCT03549696): An IL-1 inhibitor being tested for genital ulcers, with 45% response rate in a 2023 sub-study [NEJM].
The WHO’s Global Rheumatology Alliance is also pushing for HLA-B51 testing kits to be included in primary care toolkits by 2030, aiming to cut diagnostic delays by 50%. “We need to move from ‘treat the symptoms’ to ‘treat the mechanism,’” said Dr. Ali Asker, a rheumatologist at Tehran University of Medical Sciences. “The next decade will focus on personalized immunotherapy—targeting the specific immune pathways in each patient.”
For now, patients should advocate for biopsy confirmation before assuming an STI diagnosis and ask about HLA-B51 testing if Behçet’s is suspected. “This case is a wake-up call,” said Dr. Davis. “The tools exist to diagnose and treat Behçet’s early—we just need to use them.”
References
- International Study Group Criteria for Behçet’s Disease (1990) – The Lancet
- EULAR Survey on Behçet’s Diagnostics (2025) – Arthritis & Rheumatology
- Neutrophil Extracellular Traps in Behçet’s (2021) – The Lancet
- CDC Herpes vs. Behçet’s Differentiation Guide
- WHO Essential Medicines List (2023)
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for diagnosis and treatment.
